Schedule 13D ownership disclosure
CELLYAN BIOTECHNOLOGY CO LTD
Ordinary Shares, par value $0.001 per share · CUSIP: G6365B104
Event date: 2025-10-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Liying WangReported CIK 0002096212
Shares: 7,150,000.00 · Class: 65%
- TUTU Business Services Limited
Shares: 7,150,000.00 · Class: 65%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-109034
- Form type
- SCHEDULE 13D
- Filer
- Hong Kong Pharma Digital Technology Holdings Ltd
- CIK
- CIK 2007702
- Filed
- Nov 12, 2025
- Reporting period
- Oct 06, 2025
- Description
- Schedule 13D beneficial ownership